EFFICACY plus SAFETY OF PALBOCICLIB (P) IN PATIENTS (PTS) ≤50 Y WITH HORMONE RECEPTOR- POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP ANALYSIS OF 2 RANDOMIZED PHASE 3 STUDIES

被引：1
|
作者：
Cristofanilli, Massimo [5 ]
Harbeck, Nadia [1 ]
Rugo, Hope [14 ]
Castrellon, Aurelio [4 ]
Joy, Anyl A. [12 ]
Verma, Sunil [13 ]
Im, Seock-Ah [11 ]
Iyer, Shrividya [7 ]
Puyana, Kathy [8 ]
Gauthier, Eric [6 ]
Huang, Xin [9 ]
Bartlett, Cynthia Huang [10 ]
Loibl, Sibylle [3 ]
Finn, Richard S. [2 ]
机构：
[1] Brustzentrum Univ Muenchen LMU, Dept Obstet & Gynecol, Munich, Germany
[2] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Santa Monica, CA USA
[3] German Breast Grp, Neu Isenburg, Germany
[4] Mem Healthcare Syst, Breast Canc Ctr, Hollywood, CA USA
[5] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA
[6] Pfizer Inc, Global Prod Dev, San Francisco, CA USA
[7] Pfizer Oncol, Patient & Hlth Impact, New York, NY USA
[8] Pfizer Oncol, Global Product Dev, Cambridge, MA USA
[9] Pfizer Oncol, Global Prod Dev, San Diego, CA USA
[10] Pfizer Oncol, Global Med Affairs, Collegeville, PA USA
[11] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea
[12] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[13] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[14] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
BREAST | 2018年 / 41卷
关键词：
D O I：
10.1016/j.breast.2018.08.033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OR52
引用
收藏
页码：S11 / S12
页数：2
相关论文
共 50 条
  • [41] EFFICACYAND SAFETY OF PALBOCICLIB (PAL) PUS FULVESTRANT (F) BY GEOGRAPHIC REGION IN WOMEN WITH ENDOCRINERESISTANT HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAN GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) FROM PALOMA-3
    Harbeck, Nadia
    Colleoni, Marco
    Demichele, Angela
    Turner, Nicholas C.
    Cristofanilli, Massimo
    Verma, Shailendra
    Sleckman, Bethany
    Huang, Xin
    Theall, Kathy Puyana
    Bananis, Eustratios
    Masuda, Norikazu
    Im, Seock-Ah
    [J]. BREAST, 2017, 36 : S47 - S47
  • [42] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC).
    Chainitikun, Sudpreeda
    Long, James
    Rodriguez-Bautista, Ruben
    Iwase, Toshiaki
    Tripathy, Debu
    Fujii, Takeo
    Ueno, Naoto T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] HORMONE RECEPTOR-POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED/METASTATIC BREAST CANCER (ABC): TESTING PATTERNS, PRESCRIBING BEHAVIOR, AND TREATMENT OPTION PERCEPTIONS AMONG US ONCOLOGISTS
    Miller, T.
    Savill, K.
    Jeune-Smith, Y.
    Leon, B.
    Brown, M.
    Klink, A.
    Feinberg, B.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S277 - S277
  • [44] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK
    Moller, A. H.
    Oddershede, L.
    [J]. VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [45] Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) plus endocrine therapy (ET) in Asian patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
    Yap, Y. S.
    Su, F.
    Joshi, M.
    Chiu, J.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Deore, U.
    Babbar, N.
    Balbin, A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S459 - S460
  • [46] Efficacy and safety of palbociclib (PAL) plus letrozole (LET) as first-line therapy in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2
    Gelmon, Karen A.
    Castrellon, Aurelio
    Joy, Anil A.
    Walshe, Janice M.
    Ettl, Johannes
    Mukai, Hirofumi
    Park, In Hae
    Lu, Dongrui R.
    Mori, Ave
    Bananis, Eustratios
    Dieras, Veronique
    Finn, Richard S.
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [47] Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review
    Carter, Gebra Cuyun
    Mohanty, Maitreyee
    Stenger, Keri
    Guimaraes, Claudia Morato
    Singuru, Shivaprasad
    Basa, Pradeep
    Singh, Sheena
    Tongbram, Vanita
    Kuemmel, Sherko
    Guarneri, Valentina
    Tolaney, Sara M.
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 6537 - 6566
  • [48] Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
    Gelmon, Karen A.
    Cristofanilli, Massimo
    Rugo, Hope S.
    DeMichele, Angela M.
    Joy, Anil A.
    Castrellon, Aurelio
    Sleckman, Bethany
    Mori, Ave
    Theall, Kathy Puyana
    Lu, Dongrui R.
    Huang, Xin
    Bananis, Eustratios
    Finn, Richard S.
    Slamon, Dennis J.
    [J]. BREAST JOURNAL, 2020, 26 (03): : 368 - 375
  • [49] COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED/METASTATIC BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE
    Hettle, R.
    Suri, G.
    Misty, R.
    Chandiwana, D.
    Lee, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A433 - A433
  • [50] COST-EFFECTIVENESS ANALYSIS OF CAPIVASERTIB PLUS FULVESTRANT IN HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2-) NEGATIVE ADVANCED BREAST CANCER: A US PAYER PERSPECTIVE
    Liang, X.
    Tan, C. J.
    Yu, B.
    Malone, D. C.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S247 - S247
12345